Ruxolitinib cream 1.5% exhibits long-term safety in pediatric atopic dermatitis

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.
“The most important thing when we’re treating children with atopic dermatitis is to be able to be reassured about safety,” Amy S. Paller, MS, MD, Walter Hamlin Professor and Chair of Dermatology, professor of pediatrics and director of the Skin Biology and Diseases Resource-based Center at Northwestern University’s Feinberg School of Medicine, told

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.
“The most important thing when we’re treating children with atopic dermatitis is to be able to be reassured about safety,” Amy S. Paller, MS, MD, Walter Hamlin Professor and Chair of Dermatology, professor of pediatrics and director of the Skin Biology and Diseases Resource-based Center at Northwestern University’s Feinberg School of Medicine, told